Featured Content | Scientific Sessions

(from left to right): Brahmajee K. Nallamothu, MD, MPH, FAHA, Rhoda Au, PhD, Seth Martin, MD, MHS, FAHA, and Andrea Beaton, MD, FAHA

QCOR at Sessions: mHealth strategies could help treat CVD around the world

(from left to right, top to bottom rows): Corey E. Ventetuolo, MD, MS, Magdi Yacoub, OM, FRS, Karen Joynt Maddox, MD, MPH, FAHA, Gregory Lewis, MD, Marco Guazzi, MD, PhD, FAHA, Ana Macumbi, MD, PhD, FESC, Mark T. Gladwin, MD, FAHA, and William Bain, MD

The shifting profile of cardiopulmonary COVID-19 survivors

(from left to right): Jonathan P. Piccini, MD, MHS, FAHA, and Steven A. Lubitz, MD, MPH, FAHA

Late-Breaking Science: New information in cardiac disease

(from left to right): Nasrien E. Ibrahim, MD, Stefan D. Anker, MD, PhD, and Clyde W. Yancy, MD, MSc, FAHA

The latest science in heart failure

(From left to right): Danielle Belardo, MD, Rafael Diaz, MD, and Christie Mitchell Ballantyne, MD, FAHA

Trials’ results highlight the potential for fish oil to fight COVID-19 and MK-0616 to lower cholesterol

(left to right): Jacqueline E. Tamis-Holland, MD, and Jane Armitage, FRCP, FFPH, OBE

New drugs, indications in cardiovascular disease

Researchers present research regarding aspirin and dementia, early P2Y12 inhibitors, ticagrelor reversal agent and oral factor XIa.